Articles From: Identive Moves Corporate Finance Operations to California and Names Brian Nelson as Chief Financial Officer to Idera to Present at the 2014 RBC Capital Markets’ Global Healthcare Conference


SANTA ANA, Calif.
Sign-up for Identive Promotes Jason Hart to CEO investment picks
2013/11/7
SANTA ANA, Calif.
Sign-up for Identive Reports 2013 Third Quarter Results investment picks
- Expansion of HIRSCH Access Control System Secures More Than 200 Key Entry Points for Employees and Contractors - SANTA ANA, Calif.
Sign-up for Identive Secures New Green Build Terminal for San Diego International Airport investment picks
2013/9/17
SANTA ANA, Calif., Sept.
Sign-up for Identive Showcases New Access Control Solutions for Business and Government at ASIS 2013 investment picks
SANTA ANA, Calif.
Sign-up for Identive to Hold Third Quarter 2013 Conference Call and Webcast November 7, 2013 investment picks
2013/8/8
By Darrell Delamaide WASHINGTON (MarketWatch) -- President Barack Obama decided this week to lead from behind on housing finance and it looked a lot like trying to catch up.
Sign-up for Ideology drives debate on mortgage reform investment picks
2014/1/22
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis.
Sign-up for Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease investment picks
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that it has strengthened its clinical development expertise through the addition of two industry veterans with track records of success in bringing novel therapeutic products to market.
Sign-up for Idera Expands Leadership Team and Strengthens Clinical Development Expertise in Oncology and Orphan Diseases investment picks
2014/3/12
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments’ Julian C.
Sign-up for Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or, the “Company”) today announced the closing of its previously announced underwritten public offering of 13,727,251 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 4,175,975 shares of common stock.
Sign-up for Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants investment picks
2014/2/10
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public offering price for the common stock less the $0.01 per share exercise price.
Sign-up for Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants investment picks
2014/3/13
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs.
Sign-up for Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases investment picks
2014/3/28
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.
Sign-up for Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400 investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or, the “Company”) today announced the pricing of an underwritten public offering of 13,727,251 shares of common stock for a public offering price of $1.55 per share, and pre-funded warrants to purchase up to an aggregate of 4,175,975 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant.
Sign-up for Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants investment picks
2014/2/5
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant.
Sign-up for Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or, the “Company”) today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering.
Sign-up for Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants investment picks
2014/2/4
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering.
Sign-up for Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it has entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the Company’s Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas.
Sign-up for Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas investment picks
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The objectives of the trial are to evaluate the compound’s safety, tolerability, and potential clinical activity.
Sign-up for Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström’s Macroglobulinemia investment picks
2014/3/13
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today reported its financial and operational results for the fourth quarter and year ended December 31, 2013.
Sign-up for Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended June 30, 2013, and highlighted progress in the development of its Toll-like receptor (TLR) antagonist programs.
Sign-up for Idera Pharmaceuticals Reports Second Quarter 2013 Financial Results and Corporate Highlights investment picks
2013/11/14
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today reported financial results for the quarter ended September 30, 2013 and provided a corporate update.
Sign-up for Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Thursday, November 14, 2013 to report its third quarter 2013 financial results and provide a corporate update.
Sign-up for Idera Pharmaceuticals to Host Conference Call to Report Third Quarter 2013 Financial Results on Thursday, November 14, 2013 investment picks
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.
Sign-up for Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference investment picks
2014/4/7
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation.
Sign-up for Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation investment picks
2014/3/6
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Sign-up for Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014 investment picks
2014/2/6
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16 th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. EST at the Waldorf Astoria in New York City.
Sign-up for Idera to Present at 16th Annual BIO CEO & Investor Conference investment picks
2014/2/18
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
Sign-up for Idera to Present at the 2014 RBC Capital Markets’ Global Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Identive Moves Corporate Finance Operations to California and Names Brian Nelson as Chief Financial Officer to Idera to Present at the 2014 RBC Capital Markets’ Global Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity